Healthcare solutions company Owens & Minor Inc (NYSE:OMI) on Tuesday introduced ByramConnect, a digital health platform designed to support Byram Healthcare customers managing diabetes and other chronic conditions.
Powered by the Welldoc App, the platform offers AI-driven health coaching, self-tracking and personalised insights to improve patient outcomes.
ByramConnect is an FDA-cleared class II software as a medical device intended for patients with type 1 or type 2 diabetes. Clinical studies show that users experienced improvements in A1C levels, blood pressure and weight management. The app integrates data from fitness trackers, glucose monitors, blood pressure monitors and other connected health devices.
Key features include AI-driven digital coaching, diet and nutrition support, GLP-1 medication tracking and mental well-being guidance. Patients receive personalised health reports with actionable insights to share with their healthcare providers.
The platform is available at no additional cost exclusively to Byram Healthcare diabetes customers. Eligible users will receive email invitations with an access code to download the app on iOS and Android devices.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid